China News Service, Beijing, May 8th. May 8th this year is the tenth "World Ovarian Cancer Day".
Initiated by Beijing Bethune Public Welfare Foundation, supported by Zai Lab Public Welfare, and participated by the patient community "Cancer Degree" and "Walk With You", the first women's public welfare forum "See Her Power" in the field of gynecology in my country was held recently.
This is the second consecutive year that the "See Her Power" Women's Public Welfare Forum has been held. This year's theme is the first lesson of anti-cancer, which aims to connect authoritative experts in the field of gynecological oncology, representatives of ovarian cancer patients and their families, and civil anti-cancer forces. , to create the first anti-cancer lesson for patients and their families newly diagnosed with ovarian cancer, to give more care to patients and their families, to encourage scientific and standardized treatment, and to achieve a longer and higher quality of life.
Sun Zhiwei, chairman of Beijing Bethune Public Welfare Foundation, said that women's health is an important cornerstone of national health and is of great significance to the healthy development of society.
To improve the diagnosis and treatment of ovarian cancer and improve the living conditions of patients requires the joint efforts of academia, industry, associations, enterprises and patients.
It is hoped that the continuous holding of this public welfare forum will help patients from the beginning of anti-cancer, spread scientific diagnosis and treatment knowledge, and add strength to the promotion of cancer prevention and treatment in China.
In recent years, with the development of evidence-based medicine, the treatment of ovarian cancer has made significant progress.
In the forum, experts pointed out that in terms of ovarian cancer treatment, surgery is the foundation, chemotherapy is the key, and maintenance therapy is the guarantee.
Therefore, the key to the treatment of ovarian cancer lies in thorough and high-quality surgery, standardized chemotherapy and follow-up standard PARP inhibitor maintenance therapy, which are the keys to a good prognosis for patients.
Professor Zhu Jianqing, director of the Department of Gynecologic Oncology, Cancer Hospital Affiliated to the University of Chinese Academy of Sciences, said that ovarian cancer is like a landmine, hidden deep in the body.
Early detection of ovarian cancer is conducive to complete tumor resection, the higher the possibility of radical cure, and the prolongation of the patient's life as much as possible.
"So standard, standardized cytoreductive surgery is of great significance for ovarian cancer patients."
Professor Yin Rutie, director of the Department of Oncology, Radiotherapy and Chemotherapy, West China Second Hospital, Sichuan University pointed out that chemotherapy and surgery play an equally important role in the treatment of ovarian cancer. Standardized chemotherapy can help patients remove cancer cells that are invisible to the naked eye but remain in the body.
With the advancement of science and technology, doctors have more to deal with the adverse reactions caused by different chemotherapy drugs, such as drugs to protect the gastrointestinal tract, drugs to protect the liver and kidney, etc.
Therefore, during chemotherapy, patients should not have too much psychological burden. It is recommended to adjust their mentality and actively cooperate with doctors for treatment.
Professor Wu Ming, chief physician of the Department of Obstetrics and Gynecology of Peking Union Medical College Hospital, pointed out that although ovarian cancer is the disease with the highest mortality rate and the worst prognosis among gynecological tumors, more than 90% of early ovarian cancer can be cured, and there is no lack of long-term survival for advanced ovarian cancer. Cases, if receiving regular treatment, more than 50% can live for more than 5 years.
In addition, after completing surgery and chemotherapy, patients who achieved complete remission or partial remission can further reduce recurrence, delay recurrence and obtain relatively long remission period through PARP inhibitor maintenance therapy.
During this period, the patient can live a good life, which also brings great help to the patient's entire treatment.
Today, the treatment of ovarian cancer has entered the era of chronic disease management.
"We now put forward the concept of chronic disease management of ovarian cancer, that is, doctors and patients must reach a consensus, not be too aggressive in treatment, and learn to live peacefully with it. This mentality is particularly important in tumor treatment." Peking Union Medical College Hospital Obstetrics and Gynecology Professor Pan Lingya, the chief physician of the department, emphasized that the road to fighting cancer is a protracted battle, and we must be prepared for a long-term battle.
Viewing the disease correctly and taking the first step prudently to choose the right hospital, the right doctor, and the right treatment method are the first things that new ovarian cancer patients should do.
(Finish)